about
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugsGenome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in EuropeThe case-crossover design via penalized regression.Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis.A Metabolome-Wide Association Study of Kidney Function and Disease in the General PopulationAssessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an exampleNFAT5 and SLC4A10 Loci Associate with Plasma Osmolality.Did the reporting of prognostic studies of tumour markers improve since the introduction of REMARK guideline? A comparison of reporting in published articles.Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.Lack of a specific humoral autoreactivity in sera from patients with early erythema exsudativum multiforme majus.Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study.Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis.Are Idiopathic Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Related to Drugs in Food? The Example of Phenylbutazone.Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies.Assessment of the "case-chaos" design as an adjunct to the case-control design.Serum metabolite concentrations and decreased GFR in the general population.An application of propensity score methods to estimate the treatment effect of corticosteroids in patients with severe cutaneous adverse reactions.Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study.Effects of immunomodulating therapies on mortality in patients with severe cutaneous adverse reactions in comparison with supportive care only: a systematic review.Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy.HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis.The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies.Generalized pustular eruptions: time to adapt the disease taxonomy to the genetic architecture?From Discovery to Translation: Characterization of C-Mannosyltryptophan and Pseudouridine as Markers of Kidney Function.Metabolites associate with kidney function decline and incident chronic kidney disease in the general population.Genome-Wide Association Studies of Metabolite Concentrations (mGWAS): Relevance for Nephrology.Genome-Wide Association Studies of Metabolites in Patients with CKD Identify Multiple Loci and Illuminate Tubular Transport Mechanisms.Control procedures and estimators of the false discovery rate and their application in low-dimensional settings: an empirical investigation.Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis.Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR StudyDesign choices for observational studies of the effect of exposure on disease incidenceA Novel Metabolic Signature To Predict the Requirement of Dialysis or Renal Transplantation in Patients with Chronic Kidney DiseaseGenetic studies of urinary metabolites illuminate mechanisms of detoxification and excretion in humans
P50
Q28264524-315D6C3D-423B-47BF-8584-0E7E495059FAQ28943413-88C40515-8321-4A64-9973-F012181BFE62Q36109705-342EC23A-73AC-4E0D-98F0-92F2FFAA12B9Q36318645-7918DFE3-5ABC-4BBD-845C-D172BB94BF36Q36746035-8D1F97C4-04D8-42EF-9B33-DDA222B33C20Q37236560-4CBE65B1-20A4-4297-A5C1-E90536A2649EQ38404295-375D8C4C-A011-4FE6-92B7-0101D932FCF3Q38671095-8A729C46-B4FC-4A0B-8AC3-266A84FF7D7CQ39068061-0C2E9E43-0F22-446B-9218-99BB6C0284ABQ39142979-A5536B69-0E82-41BD-BF51-981F64D282EFQ40241303-1E73C91A-1539-491B-AB93-55211651F29DQ40257255-4EC5DE3C-D5A3-4E19-B7C8-7AC9DB2CC454Q40370835-D81FB0E6-CF81-4DE3-B9EA-4977A536B481Q40687484-9D4ADA70-351D-4231-A438-5CD86B27AC47Q43453183-9DE036F1-E0C7-4F64-95DA-63EAA7228219Q44085518-EC6444D0-3706-4B36-BE6D-16565E3643CFQ44689577-298FF076-6F26-443C-AE04-336B4448798AQ44989249-565AF502-BAAA-46B7-B4F1-5936D123DBA1Q45749874-67512FA4-3F80-47AA-827A-6A2C5522B31EQ46066861-0921139D-8DB7-4BAA-B3EA-F25B74C6FF5AQ46712166-FF484D2B-3514-441D-98BD-BBFC330FC2FDQ46859144-13CED839-F38F-4119-BDB2-1593116595F6Q47703047-BCF5BE71-E73F-4A9E-9290-44B4E2F4D5B1Q47755269-DFFA68DD-C64D-47F5-AB62-0D9458BE85F9Q48130724-02B313D5-6329-4849-A630-95212D054431Q51216532-DC1558DC-1105-4F8A-BC1D-40E7A75A0EFEQ52618379-845AE4D9-E4BC-459C-A7DA-CB4453FD79F6Q52726273-80471F1A-33C1-4405-8AF6-B34D794D9554Q53273276-4D11BC7B-1CF3-4DF2-93B1-B39A333E8332Q55056989-6DA2670E-3799-48DC-988A-BC323DBD523BQ59566851-55925B62-AE0B-4038-BD5D-71D467E25C9FQ91853174-E196A0B6-0C77-4D4C-89D9-0AAF97E665F5Q92003408-0026562F-9AC5-4C2F-B58C-2249BBC0E53CQ92784883-E4D7688D-0B74-41F0-8474-BBD43DD0B96B
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
statisticus
@nl
հետազոտող
@hy
name
Peggy Sekula
@ast
Peggy Sekula
@en
Peggy Sekula
@es
Peggy Sekula
@nl
Peggy Sekula
@sl
type
label
Peggy Sekula
@ast
Peggy Sekula
@en
Peggy Sekula
@es
Peggy Sekula
@nl
Peggy Sekula
@sl
prefLabel
Peggy Sekula
@ast
Peggy Sekula
@en
Peggy Sekula
@es
Peggy Sekula
@nl
Peggy Sekula
@sl
P214
P227
P21
P214
P227
1024816036
P31
P496
0000-0003-2263-447X
P734
P735
P7859
viaf-258604659